Clinical Trial

A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine

Study acronym: PROSPECT-2
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
To find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.
Protocol Amendment History 42 amendments
This ClinicalTrials.gov record has been amended 42 times since 2021-07-07; most recent amendment 2026-07-13.
Trial Details
NCT Number NCT04965675
Lead Sponsor H. Lundbeck A/S
Conditions Chronic Migraine in Children
Enrollment 285 participants
Start Date 2021-06-30
Primary Completion 2026-09-05 (estimated)
Study Completion 2026-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-14